Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T-cells (ACTolog; IMA101) in Patients With Relapsed and/or Refractory Solid Cancers
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; IMA 101 (Primary) ; Interleukin-2 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms ACTolog
- Sponsors Immatics US
- 05 Jul 2017 Status changed from not yet recruiting to recruiting.
- 16 May 2017 Planned initiation date changed from 31 Oct 2017 to 1 Jul 2017.
- 09 May 2017 Planned End Date changed from 1 Sep 2018 to 31 Aug 2019.